Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...
Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin sites for new plants beyond a $3 billion project the ...
Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.
Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh ...
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...
Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
Copyright 2024 The Associated Press. All Rights Reserved. David Ricks, chair and CEO of Eli Lilly, fields a question ...
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Akash Tewari has given his Buy rating due to a combination of factors surrounding Eli Lilly & Co’s strategic ...